WB result of RANKL Recombinant Rabbit mAb
Primary antibody: RANKL Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: Raji whole cell lysate 20 µg
Lane 2: THP-1 whole cell lysate 20 µg
Lane 3: BxOC-3 whole cell lysate 20 µg
Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 35 kDa
Observed MW: 37 kDa
This blot was developed with high sensitivity substrate
RANKL Recombinant Rabbit mAb (S-2636-218)
RANKL Recombinant Rabbit mAb (S-2636-218)
Price:
Regular price
$131.00 SGD
Regular price
Sale price
$131.00 SGD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | RANKL |
| Synonyms | Tumor necrosis factor ligand superfamily member 11; Osteoclast differentiation factor (ODF); Osteoprotegerin ligand (OPGL); Receptor activator of nuclear factor kappa-B ligand (RANKL); TNF-related activation-induced cytokine (TRANCE); CD254; OPGL; TRANCE; TNFSF11 |
| Immunogen | Recombinant Protein |
| Location | Cell membrane |
| Accession | O14788 |
| Clone Number | S-2636-218 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | WB |
| Reactivity | Hu |
| Positive Sample | Raji, THP-1, BxOC-3 |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
| application | dilution | species |
| WB | 1:1000 | Hu |
Background
RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand), also known as TNFSF11, is a critical type II transmembrane protein belonging to the TNF superfamily that functions as the principal stimulatory factor for osteoclast formation, activation, and survival by binding to its receptor RANK on osteoclast precursor cells, thereby playing an essential role in bone remodeling, calcium metabolism, and immune responses, while its overexpression is implicated in various bone-related diseases such as osteoporosis, rheumatoid arthritis, and bone metastases, making it a key therapeutic target for denosumab and other RANKL inhibitors.
Picture
Picture
Western Blot
